

Glaucoma

**A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension**

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03293992 BP39863

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and latanoprost 0.005% as active comparator (Part B).

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03293992 BP39863**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years & <= 90 Years

**Healthy Volunteers**  
No

---